Drug Price Regulation: What’s Patent Law Got to Do With It?

June 3, 2022 10:45am

Jacob Oyloe
Senior Director, Patents
AstraZeneca

Adam Mossoff
Professor of Law
Antonin Scalia Law School, George Mason University

Melissa Brand
Intellectual Property Counsel
Radius Health

Sophia Gaulkin
Attorney
Hyman, Phelps and McNamara

The correlation between a patent system and the costs and logistics of drug development is an issue that will trickle down to your daily patent prosecution practice. Our panelist will get you up to speed on the necessary backdrop and then extrapolate the impact on patent prosecution. Points of discussion will include:

  • A brief overview of drug pricing and how it works in the US and EU
  • How the world is currently reacting to escalating drug costs and access issues (e.g., price controls, compulsory licensing)
  • Current US and Global legislative and other reform efforts that aim to impact the type of portfolio you can build and how it can be asserted (e.g., the TRIPS Waiver)
    • Redeveloping patent prosecution strategies in light of these developments
  • Negotiating compulsory licensing to your advantage